129 related articles for article (PubMed ID: 18454510)
1. A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.
Ferenci P; Brunner H; Laferl H; Scherzer TM; Maieron A; Strasser M; Fischer G; Hofer H; Bischof M; Stauber R; Gschwantler M; Steindl-Munda P; Staufer K; Löschenberger K;
Hepatology; 2008 Jun; 47(6):1816-23. PubMed ID: 18454510
[TBL] [Abstract][Full Text] [Related]
2. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin.
Fried MW; Jensen DM; Rodriguez-Torres M; Nyberg LM; Di Bisceglie AM; Morgan TR; Pockros PJ; Lin A; Cupelli L; Duff F; Wang K; Nelson DR
Hepatology; 2008 Oct; 48(4):1033-43. PubMed ID: 18697207
[TBL] [Abstract][Full Text] [Related]
3. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.
Ferenci P; Laferl H; Scherzer TM; Gschwantler M; Maieron A; Brunner H; Stauber R; Bischof M; Bauer B; Datz C; Löschenberger K; Formann E; Staufer K; Steindl-Munda P;
Gastroenterology; 2008 Aug; 135(2):451-8. PubMed ID: 18503773
[TBL] [Abstract][Full Text] [Related]
4. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.
Reddy KR; Shiffman ML; Rodriguez-Torres M; Cheinquer H; Abdurakhmanov D; Bakulin I; Morozov V; Silva GF; Geyvandova N; Stanciu C; Rabbia M; McKenna M; Thommes JA; Harrison SA;
Gastroenterology; 2010 Dec; 139(6):1972-83. PubMed ID: 20816836
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.
Shiffman ML; Suter F; Bacon BR; Nelson D; Harley H; Solá R; Shafran SD; Barange K; Lin A; Soman A; Zeuzem S;
N Engl J Med; 2007 Jul; 357(2):124-34. PubMed ID: 17625124
[TBL] [Abstract][Full Text] [Related]
6. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.
Ferenci P; Laferl H; Scherzer TM; Maieron A; Hofer H; Stauber R; Gschwantler M; Brunner H; Wenisch C; Bischof M; Strasser M; Datz C; Vogel W; Löschenberger K; Steindl-Munda P;
Gastroenterology; 2010 Feb; 138(2):503-12, 512.e1. PubMed ID: 19909752
[TBL] [Abstract][Full Text] [Related]
7. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.
Yu ML; Dai CY; Huang JF; Hou NJ; Lee LP; Hsieh MY; Chiu CF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Gut; 2007 Apr; 56(4):553-9. PubMed ID: 16956917
[TBL] [Abstract][Full Text] [Related]
8. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
McHutchison JG; Lawitz EJ; Shiffman ML; Muir AJ; Galler GW; McCone J; Nyberg LM; Lee WM; Ghalib RH; Schiff ER; Galati JS; Bacon BR; Davis MN; Mukhopadhyay P; Koury K; Noviello S; Pedicone LD; Brass CA; Albrecht JK; Sulkowski MS;
N Engl J Med; 2009 Aug; 361(6):580-93. PubMed ID: 19625712
[TBL] [Abstract][Full Text] [Related]
9. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.
Pockros PJ; Nelson D; Godofsky E; Rodriguez-Torres M; Everson GT; Fried MW; Ghalib R; Harrison S; Nyberg L; Shiffman ML; Najera I; Chan A; Hill G
Hepatology; 2008 Aug; 48(2):385-97. PubMed ID: 18570306
[TBL] [Abstract][Full Text] [Related]
10. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial.
Jacobson IM; Brown RS; Freilich B; Afdhal N; Kwo PY; Santoro J; Becker S; Wakil AE; Pound D; Godofsky E; Strauss R; Bernstein D; Flamm S; Pauly MP; Mukhopadhyay P; Griffel LH; Brass CA;
Hepatology; 2007 Oct; 46(4):971-81. PubMed ID: 17894303
[TBL] [Abstract][Full Text] [Related]
11. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
12. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial.
Rodriguez-Torres M; Slim J; Bhatti L; Sterling R; Sulkowski M; Hassanein T; Serrão R; Sola R; Bertasso A; Passe And S; Stancic S
HIV Clin Trials; 2012; 13(3):142-52. PubMed ID: 22592094
[TBL] [Abstract][Full Text] [Related]
13. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS
Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016
[TBL] [Abstract][Full Text] [Related]
15. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial.
Mangia A; Minerva N; Bacca D; Cozzolongo R; Ricci GL; Carretta V; Vinelli F; Scotto G; Montalto G; Romano M; Cristofaro G; Mottola L; Spirito F; Andriulli A
Hepatology; 2008 Jan; 47(1):43-50. PubMed ID: 18069698
[TBL] [Abstract][Full Text] [Related]
16. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.
Buti M; Sanchez-Avila F; Lurie Y; Stalgis C; Valdés A; Martell M; Esteban R
Hepatology; 2002 Apr; 35(4):930-6. PubMed ID: 11915041
[TBL] [Abstract][Full Text] [Related]
17. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
Rustgi VK; Esposito S; Hamzeh FM; Shiffman ML
Aliment Pharmacol Ther; 2008 Mar; 27(5):433-40. PubMed ID: 18081737
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial adding fluvastatin to peginterferon and ribavirin for naïve genotype 1 hepatitis C patients.
Bader T; Hughes LD; Fazili J; Frost B; Dunnam M; Gonterman A; Madhoun M; Aston CE
J Viral Hepat; 2013 Sep; 20(9):622-7. PubMed ID: 23910646
[TBL] [Abstract][Full Text] [Related]
19. Peginterferon alpha-2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels.
Calleja JL; García-Samaniego J; Ruiz-Antorán B; Trapero M; Morillas R; de la Revilla J; Erdozaín JC; Espinosa MD; Suárez D; Solá R; Romero-Gómez M; Baños F; Alvarez MA;
J Gastroenterol Hepatol; 2012 Nov; 27(11):1705-10. PubMed ID: 22742958
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents.
Sokal EM; Bourgois A; Stéphenne X; Silveira T; Porta G; Gardovska D; Fischler B; Kelly D
J Hepatol; 2010 Jun; 52(6):827-31. PubMed ID: 20400194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
